CN1985814A - Monomer medicine for treating rheumatic arthritis and rheumatoid arthritis - Google Patents
Monomer medicine for treating rheumatic arthritis and rheumatoid arthritis Download PDFInfo
- Publication number
- CN1985814A CN1985814A CN 200510200859 CN200510200859A CN1985814A CN 1985814 A CN1985814 A CN 1985814A CN 200510200859 CN200510200859 CN 200510200859 CN 200510200859 A CN200510200859 A CN 200510200859A CN 1985814 A CN1985814 A CN 1985814A
- Authority
- CN
- China
- Prior art keywords
- theanine
- application
- medicine
- present
- arthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 67
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 27
- 201000003068 rheumatic fever Diseases 0.000 title claims abstract description 26
- 239000000178 monomer Substances 0.000 title description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 346
- 229940026510 theanine Drugs 0.000 claims abstract description 121
- 230000036541 health Effects 0.000 claims abstract description 58
- 208000002193 Pain Diseases 0.000 claims abstract description 24
- 230000036407 pain Effects 0.000 claims abstract description 23
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 claims description 64
- 238000002360 preparation method Methods 0.000 claims description 41
- 206010003246 arthritis Diseases 0.000 claims description 28
- 230000005764 inhibitory process Effects 0.000 claims description 11
- 230000002917 arthritic effect Effects 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 8
- 230000000694 effects Effects 0.000 abstract description 21
- 238000005516 engineering process Methods 0.000 abstract description 8
- 238000009776 industrial production Methods 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- DATAGRPVKZEWHA-RXMQYKEDSA-N (2r)-2-azaniumyl-5-(ethylamino)-5-oxopentanoate Chemical compound CCNC(=O)CC[C@@H](N)C(O)=O DATAGRPVKZEWHA-RXMQYKEDSA-N 0.000 description 15
- 239000000284 extract Substances 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- 244000269722 Thea sinensis Species 0.000 description 13
- 206010042674 Swelling Diseases 0.000 description 12
- 230000008961 swelling Effects 0.000 description 12
- 239000002775 capsule Substances 0.000 description 11
- 235000013616 tea Nutrition 0.000 description 11
- 210000002683 foot Anatomy 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 238000000855 fermentation Methods 0.000 description 9
- 230000004151 fermentation Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- -1 fragrant Tea Co. Chemical compound 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229940013618 stevioside Drugs 0.000 description 4
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 4
- 235000019202 steviosides Nutrition 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- DGIMBMZJSZEZJD-ZLELNMGESA-N (2s)-2-amino-5-(ethylamino)-5-oxopentanoic acid Chemical compound CCNC(=O)CC[C@H](N)C(O)=O.CCNC(=O)CC[C@H](N)C(O)=O DGIMBMZJSZEZJD-ZLELNMGESA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 235000008098 Oxalis acetosella Nutrition 0.000 description 1
- 241001119522 Paullinia pinnata Species 0.000 description 1
- 235000010240 Paullinia pinnata Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to the application of theanine in preparing medicine and health product for preventing and treating rheumatic arthritis and rheumatoid arthritis, and belongs to the field of medicine and health product technology. Theanine as medicine can eliminate or relieve pain of rheumatic arthritis and rheumatoid arthritis and has obvious curative effect and no toxic side effect. The present invention is suitable for industrial production.
Description
Technical field
The present invention relates to the medicine or the healthcare applications of theanine, be specifically related to theanine and treat and/or prevent application in arthritic medicine or the health product in preparation, relate in particular to theanine and treat and/or prevent the medicine of rheumatism or rheumatoid arthritis or the application in the health product, belong to medicine or field of health care products in preparation.
Background technology
Arthritis is arthropathy, especially rheumatic arthritis common, multiple, refractory and rheumatoid arthritis, has a strong impact on patient's health and orthobiosis.Western medicine arthritis is particularly treated rheumatic arthritis and rheumatoid arthritis at present, and aspirin commonly used, Phenylbutazone, naproxen, hormone and penicillin etc. still, are difficult to thorough healing, and side effect clearly.Treatment by Chinese herbs, slow curative effect also is difficult to radical cure.For arthritis, especially for the drug research of rheumatic arthritis, rheumatoid arthritis, become the emphasis that the world of medicine pays close attention to, development good effect, medicine nontoxic, the treatment of arthritis that has no side effect are urgent and important.
Theanine (Theanine, Tea, ammonia acid) is a kind of distinctive aminoacid that exists in the Folium Camelliae sinensis, also is the characteristic aminoacid of Folium Camelliae sinensis, and 1949, L-theanine (L-Theanine) at first was found in Folium Camelliae sinensis.
Theanine is a kind of monomeric compound, and molecular formula is C
7H
14O
3N
2(or C
7H
14N
2O
3), formal name used at school is a glutamy ethamine, according to the difference of type different titles is arranged, and is N-ethyl-L-glutaminate as L-theanine formal name used at school.Present known theanine comprises L-theanine, D-theanine, DL-theanine.
The L-theanine is the material that constitutes Folium Camelliae sinensis (especially green tea) local flavor, thinks at present, and except pestering, theanine exists only in and produces in the tea plant.The L-theanine accounts between the 1%-2% of dry weight of tea leaves, and it exists with a kind of free form and is aminoacid main in the Folium Camelliae sinensis, is about 50% of all free amino acids.
Theanine has good stability, has now and studies show that continue in 5 fens clock times of 121 ℃ of high temperature, theanine is not degraded; Ambient stable at pH3.0-6.6; Beverage stores 1 year at 25 ℃, and theanine shows well stability.Theanine just is decomposed in the time of 214-215 ℃.
Theanine is a kind of material with physiological function, studies show that, the main effect of theanine has: anticancer, blood pressure lowering, improvement sleep, improve immunity, separate the fatigue that disappears, loosen emotion, improve attention.L-theanine, D-theanine, DL-theanine all have above-mentioned physiological function.The L-theanine has been used as food additive in addition, is used to improve flavour of food products.
The preparation of theanine has several different methods, mainly contains: extraction from Folium Camelliae sinensis, chemosynthesis, enzyme effect transform.The technology of preparing of theanine is very ripe, and its product has reached 100% as monomeric content.There is the report of many theanine preparation methoies China and foreign countries: the open CN1546461 of Chinese patent, CN1554642, CN1557841, CN1587258, CN1415599, CN1560025, foreign patent EP1544306, JP2004203822, JP2004010545, JP2002325596, JP2001278848, JP2000026383, JP11225789, JP9263573, JP5328986, JP5068578, JP5070419, JP3187388, JP58040094, WO0173038 has put down in writing the extracting method of theanine, the chemical synthesis process of theanine, the enzyme effect production method of theanine, fermentation method etc.
Theanine can suitability for industrialized production, mainly extracts from Folium Camelliae sinensis, and some synthetic theanine are also arranged.Japan Taiyo Kagaku Co., Ltd., Shanghai ask moral biochemical industry company limited, Shanghai with equal suitability for industrialized production theanine (mainly being the L-theanine) such as fragrant Tea Co., Ltd, Wuxi Taiyo Green Power Co., Ltd.'s production, the good biochemical technology company limited of Hangzhou latitude, Hunan Keyuan Bio-products Co., Ltd., Xinglin Traditional Chinese Medicine Research Co Ltd, Hangzhou.At present the theanine commodity in, the content of L-theanine also has 100% content between 30%-99%.Mainly according to purposes production, the general medicine purposes is higher with content, and food applications is low with content, and does not technically have problems.The commodity theanine of asking moral biochemical industry company limited to produce such as Shanghai, the content height to 99% of L-theanine wherein, price is 1500 yuan/kilogram of RMB; Latitude good biochemical technology company limited in Hangzhou has the L-theanine of 100% content.Quzhou peace letter chemical industry company limited, Shanghai rich sugarcane chemical industry company limited, general section of Zhejiang University chemical industry company limited etc. have DL-theanine, D-theanine, content 99%.The chemical reagent that all types of theanine are all arranged in addition.
Up to the present, the relevant theanine of Shang Weijian is used for the treatment of and/or prevents the report of arthritis, rheumatic arthritis or rheumatoid arthritis.
Summary of the invention
The purpose of this invention is to provide theanine and treat and/or prevent application in arthritic medicine or the health product in preparation.
Purpose of the present invention specifically provides theanine to treat and/or prevent the medicine of rheumatic arthritis or the application in the health product in preparation.
Purpose of the present invention especially specifically provides theanine to treat and/or prevent the medicine of rheumatoid arthritis or the application in the health product in preparation.
Technical scheme of the present invention: theanine treats and/or prevents application in arthritic medicine or the health product in preparation.
Specifically, technical scheme of the present invention: theanine treats and/or prevents the medicine of rheumatic arthritis or the application in the health product in preparation.
Especially specifically, technical scheme of the present invention: theanine treats and/or prevents the medicine of rheumatoid arthritis or the application in the health product in preparation.
Application of the present invention, described treating and/or preventing is treatment.
Application of the present invention, described treating and/or preventing is prevention.
Application of the present invention, described medicine or health product are medicine.
Application of the present invention, described medicine or health product are health product.
Application of the present invention, described health product comprise health care medicine, health food.
Application of the present invention, described health product are health care medicine.
Application of the present invention, described health product are health food.
Application of the present invention is characterized in that theanine treats and/or prevents application in the arthritic medicine in preparation.
Application of the present invention is characterized in that the application of theanine in the medicine of preparation treatment of arthritis.
Application of the present invention is characterized in that the application of theanine in the arthritic medicine of preparation prevention.
Application of the present invention is characterized in that theanine treats and/or prevents application in the arthritic health product in preparation.
Application of the present invention is characterized in that the application of theanine in the health product of preparation treatment of arthritis.
Application of the present invention is characterized in that the application of theanine in the arthritic health product of preparation prevention.
Application of the present invention is characterized in that theanine treats and/or prevents application in the medicine of rheumatic arthritis in preparation.
Application of the present invention is characterized in that the application of theanine in the medicine of preparation treatment rheumatic arthritis.
Application of the present invention is characterized in that the application of theanine in the medicine of preparation prevention rheumatic arthritis.
Application of the present invention is characterized in that theanine treats and/or prevents application in the health product of rheumatic arthritis in preparation.
Application of the present invention is characterized in that the application of theanine in the health product of preparation treatment rheumatic arthritis.
Application of the present invention is characterized in that the application of theanine in the health product of preparation prevention rheumatic arthritis.
Application of the present invention is characterized in that theanine treats and/or prevents application in the medicine of rheumatoid arthritis in preparation.
Application of the present invention is characterized in that the application of theanine in the medicine of preparation treatment rheumatoid arthritis.
Application of the present invention is characterized in that the application of theanine in the medicine of preparation prevention rheumatoid arthritis.
Application of the present invention is characterized in that theanine treats and/or prevents application in the health product of rheumatoid arthritis in preparation.
Application of the present invention is characterized in that the application of theanine in the health product of preparation treatment rheumatoid arthritis.
Application of the present invention is characterized in that the application of theanine in the health product of preparation prevention rheumatoid arthritis.
Application of the present invention, the described arthritis that treats and/or prevents comprises and eliminating or the inhibition arthritis.
Application of the present invention, the described rheumatic arthritis that treats and/or prevents comprises and eliminating or the inhibition arthritis.
Application of the present invention, the described rheumatoid arthritis that treats and/or prevents comprises and eliminating or the inhibition arthritis.
Described elimination or inhibition arthritis also can be described as antiinflammatory.
Application of the present invention is characterized in that described treating and/or preventing to eliminating or the inhibition arthritis.
Application of the present invention, the described arthritis that treats and/or prevents comprises and eliminating or inhibition arthritis pain.
Application of the present invention, the described rheumatic arthritis that treats and/or prevents comprises and eliminating or inhibition arthritis pain.
Application of the present invention, the described rheumatoid arthritis that treats and/or prevents comprises and eliminating or inhibition arthritis pain.
Described elimination or inhibition arthritis pain also can be described as analgesia or pain relieving.
Application of the present invention is characterized in that described treating and/or preventing to eliminating or inhibition arthritis pain.
Application of the present invention, described arthritis comprises rheumatic arthritis.
Application of the present invention, described arthritis comprises rheumatoid arthritis.
Application of the present invention, described arthritis comprises non-rheumatic arthritis.
Application of the present invention, described arthritis comprises osteoarthritis.
Application of the present invention, described theanine comprise the theanine that extracts from Folium Camelliae sinensis (or other plant); Comprise synthetic theanine; Comprise the theanine that the enzyme effect transforms; Comprise the theanine that fermentation mode is produced.
Application of the present invention, described theanine comprise the theanine that extracts from Folium Camelliae sinensis (or other plant).
Application of the present invention, described theanine comprises synthetic theanine; Comprise the theanine that the enzyme effect transforms.
Application of the present invention, described theanine comprise the theanine that the enzyme effect transforms.
Application of the present invention, described theanine comprise the theanine that fermentation mode is produced.
Application of the present invention, described theanine comprise L-theanine, D-theanine, DL-theanine.
Application of the present invention, described theanine are the L-theanine.
Application of the present invention, described theanine are the D-theanine.
Application of the present invention, described theanine are the DL-theanine.
Application of the present invention owing to the L-theanine is used as food additive, and has more advantage at present economically.Therefore the L-theanine as the present invention use preferred.
The preparation method of theanine has multiple report, belongs to known technology and maturation process, and the commodity of existing suitability for industrialized production.
Application of the present invention, described theanine are extract, specifically are the theanine extract that especially extracts from Folium Camelliae sinensis from the plant that contains theanine, the i.e. theanine that extracts from plant or Folium Camelliae sinensis.
Application of the present invention, the described theanine that extracts from Folium Camelliae sinensis comprises the theanine that extracts from Folium Camelliae sinensis or plant.
Application of the present invention, the described theanine that extracts from Folium Camelliae sinensis comprise the theanine that all kinds Folium Camelliae sinensis extracts.Specifically: comprise the theanine that from unfermentable Folium Camelliae sinensis, extracts; Comprise the theanine that from the Folium Camelliae sinensis of half fermentation, extracts; Comprise the theanine that from the Folium Camelliae sinensis of full fermentation, extracts.
The tea of the tea of described unfermentable tea, half fermentation, full fermentation is the classification on the Tea Science meaning.Unfermentable tea, typical in green tea; The tea of half fermentation, typical in Folium Camelliae sinensis, and scented tea; The tea of full fermentation, typical in black tea.
Application of the present invention, described theanine comprise theanine derivant.
The derivant of described theanine comprises the salt of theanine, theanine is a seed amino acid, it is biochemical general knowledge that aminoacid energy chelated mineral particle becomes salt, and preparing amino acid salts by aminoacid equally is common known technology, such as existing commodity amino acid calcium.
The theanine or derivatives thereof all can be used as preparation and treats and/or prevents arthritic medicine or health product, and especially preparation treats and/or prevents the medicine or the health product of rheumatic or rheumatoid arthritis,
Application of the present invention, described medicine oral administration, Sublingual, external, transdermal, injection, instillation, mucosa, spraying, transfusion, rectum or parenterai administration.
Application of the present invention, the administration of described health product oral administration.
Application of the present invention can only prepare medicine or health product with a kind of theanine, also can prepare medicine or health product together with theanine dissimilar more than two kinds.
Theanine or derivatives thereof of the present invention, be that medicine is or/and the main active constituent of health product, when the preparation dosage form, can also comprise that adding one or more is selected from excipient substances such as conventional excipient, flavoring agent, disintegrating agent, antiseptic, lubricant, wetting agent, binding agent, solvent, thickening agent, solubilizing agent, makes any dosage form that is suitable for drug use clinically or uses as health product.
Application of the present invention, described medicine comprises tablet, pill, capsule, granule, liposome, oral liquid, injection, infusion solution, aerosol or nasal drop.
Application of the present invention, described health product are oral formulations.
Application of the present invention, the mass percentage content of described theanine in medicine or health product is 0.5% to 100%.
Application of the present invention, the mass percentage content of described theanine in medicine or health product is 1% to 100%.
Application of the present invention, the mass percentage content of described theanine in medicine or health product is 1% to 99%.
Application of the present invention, the mass percentage content of described theanine in medicine or health product is 5% to 98%.
Application of the present invention, the mass percentage content of described theanine in medicine or health product is 10% to 95%.
Application of the present invention, the mass percentage content of described theanine in medicine or health product is 20% to 90%.
Application of the present invention, the mass percentage content of described theanine in medicine or health product is 50% to 80%.
Existing toxicological experiment shows that theanine does not have animal dead when 5000mg/kg, therefore can think nontoxic, and any dosage below 5000mg/kg all is fine.
Application of the present invention, every day, the people of theanine used (or taking) amount to be 0.1mg/kg-300mg/kg; That preferable is 0.5mg/kg-100mg/kg; That better is 5mg/kg-80mg/kg.
Application of the present invention, the implication of described " medicine and/or health product " are that theanine can be used to prepare medicine, also can be used to prepare health product; The preparation of theanine preparation can be used as drug use, also can be used as health product and uses.
Because theanine extracts from bread and cheese Folium Camelliae sinensis, does not have poison, therefore can be applied to health product.
Pharmacodynamic experiment of the present invention
One, antiinflammatory test
1, to the influence of adjuvant arthritis rats
40 of rats, male and female half and half, body weight 150 ± 8.2g is divided into experimental group and matched group at random, 10 every group.
With L-theanine (purity 99%) is the experiment medicine, and consumption enlarges or geometric ratio by the recommendation consumption (10mg/kg) of adult's every day, designs high, medium and low 3 experimental grouies, high dose group 100mg/kg; Middle dosage group 30mg/kg; Low dose group 10mg/kg; The biological saline of matched group.Irritate stomach with the aqueous solution per os and give, every day 1 time is in injection Freund ' s Freund's complete adjuvant beginning in preceding 2 hours administration, administration in continuous 14 days.
Cause inflammation in the subcutaneous injection of the right back toes of animal Freund ' s Freund's complete adjuvant 0.05ml (by the literature method preparation).Injection adjuvant is before and after in 14 days, changes with the vernier caliper measurement rat right side, left back toes center thickness in per 2 days, and measures the swelling rate.And so that scorching before and cause the swelling degree of the left and right sides hallux of measuring in the 6th, 8,10,12 and 14 day scorching back, the swelling rate of calculating, and the comparison that takes statistics.
Theanine the results are shown in Table 1 and table 2 to the therapeutical effect of adjuvant-induced arthritis.
Table 1 L-theanine to the influence (right back foot) of rat assist agent arthritis (X ± S, n=10)
| Group | Number of animals (only) | Cause the scorching front foot sole of the foot thick (mm) | Cause scorching back pedal swelling rate (%) | ||||
| 6 days | 8 days | 10 days | 12 days | 14 days | |||
| Dosage group high dose group in the matched group low dose group | 10 10 10 10 | 5.25±0.55 5.26±0.65 5.28±0.51 5.27±0.56 | 72.50±20.34 61.21±14.39 58.60±15.15 49.35±14.91 | 74.68±21.35 59.75±14.68 52.41±15.15 43.90±15.19 | 79.54±20.24 57.25±15.73 51.21±14.12 40.54±14.56 | 84.38±15.59 51.9±12.35 41.89±12.91 34.45±15.12 | 91.39±26.24 5.073±19.09 35.41±14.15 27.59±12.35 |
Table 2 L-theanine to the influence (left back foot) of rat assist agent arthritis (X ± SD, n=10)
| Group | Number of animals (only) | Cause the scorching front foot sole of the foot thick (mm) | Cause scorching back pedal swelling rate (%) | ||||
| 6 days | 8 days | 10 days | 12 days | 14 days | |||
| Dosage group high dose group in the matched group low dose group | 10 10 10 10 | 5.15±0.54 5.20±0.49 5.19±0.50 5.22±0.51 | 3.50±0.35 5.19±1.12 5.12±1.15 4.91±1.30 | 5.74±1.45 5.10±1.21 4.81±1.35 4.89±1.09 | 7.12±0.89 5.05±1.03 4.79±1.21 4.60±1.05 | 7.99±1.05 5.01±1.09 4.71±1.32 4.52±1.15 | 8.20±1.04 4.93±1.05 4.69±1.12 3.79±1.34 |
Table 1 and table 2 show that the L-theanine has the obvious suppression effect to rat assist agent arthritis.
2, theanine brings out the influence of foot swelling to rat carrageenan
40 of rats, male and female half and half, body weight 180 ± 20g divides experimental group and matched group at random, 10 every group.
With L-theanine (purity 99%) is the experiment medicine, and consumption enlarges or geometric ratio by the recommendation consumption (10mg/kg) of adult's every day, designs high, medium and low 3 experimental grouies, high dose group 100mg/kg; Middle dosage group 30mg/kg; Low dose group 10mg/kg; The biological saline of matched group.Irritate stomach with the aqueous solution per os and give every day 1 time, continuous 4 days.
Behind the last administration 30min, in the right back sufficient plantar subcutaneous injection 1% carrageenin 0.05ml/ of rat only, so that scorching.Cause scorching front and back 30,60,120,240min rat paw volume with the sufficient volume determination instrument mensuration of Mus, the difference that causes the sufficient sole of the foot volume in scorching front and back is the swelling degree.
Theanine sees Table 3 to the effect that rat carrageenan brings out the foot swelling treatment.
Table 3 L-theanine to rat carrageenan bring out pedal swelling influence (X ± SD, n=10)
| Group | Number of animals (only) | Cause scorching front foot volume (ml) | Cause scorching back paw swelling (ml) (min) | |||
| 30 | 60 | 120 | 240 | |||
| Dosage group high dose group in the matched group low dose group | 10 10 10 10 | 1.36±0.15 1.36±0.14 1.37±0.12 1.38±0.12 | 0.38±0.12 0.32±0.13 0.30±0.13 0.21±0.09 | 0.74±0.14 0.65±0.10 0.49±0.15 0.42±0.12 | 1.08±0.21 0.90±0.14 0.81±0.13 0.75±0.10 | 1.06±0.12 0.89±0.10 0.86±0.11 0.68±0.12 |
Table 3 shows that the pedal swelling that the L-theanine brings out rat carrageenan has the obvious suppression effect.
Two, analgesic test
1, to the influence (mice hot plate method) of thermostimulation pain reaction
With 20 ± 2g mice, stimulate on input constant temperature (55 ± 0.5 ℃) hot plate to cause pain, measure pain threshold (licking metapedes with mice is the pain reaction index, and be pain threshold the incubation period of reacting with pain, and being no more than 30s with the threshold of pain is qualified mice) in advance.
Select 40 of qualified mices, male and female half and half are divided experimental group and matched group at random, 10 every group.With L-theanine (purity 99%) is the experiment medicine, and consumption enlarges or geometric ratio by the recommendation consumption (10mg/kg) of adult's every day, designs high, medium and low 3 experimental grouies, high dose group 100mg/kg; Middle dosage group 30mg/kg; Low dose group 10mg/kg; The biological saline of matched group.Irritate stomach with the aqueous solution per os and give every day 1 time, continuous 6 days.
In last administration 60min, mice dropped on constant temperature (55 ± 0.5 ℃) hot plate to stimulate cause pain, lick metapedes as the pain reaction index with mice, the record mice is from dropping into hot plate to the time that the metapedes reaction occurs licking, and takes statistics.
The pain that the L-theanine suppresses the thermostimulation generation the results are shown in Table 4.
Table 4 L-theanine to the analgesic activity (hot plate method) of mice (X ± SD, n=10)
| Group | Number of animals (only) | The pain reaction time (s) appears |
| Dosage group high dose group in the matched group low dose group | 10 10 10 10 | 23.09±6.22 29.34±8.14 32.25±7.35 39.53±8.14 |
Table 4 shows that the L-theanine can effectively suppress the pain that thermostimulation produces.
2, to the influence (mouse writhing method) of chemical stimulation pain reaction
40 of mices, male and female half and half, body weight 13 ± 2g divides experimental group and matched group at random, 10 every group.With L-theanine (purity 99%) is the experiment medicine, designs high, medium and low 3 experimental grouies, high dose group 100mg/kg; Middle dosage group 30mg/kg; Low dose group 10mg/kg; The biological saline of matched group.Irritate stomach with the aqueous solution per os and give every day 1 time, continuous 6 days.
In last administration 60min, the acetum (0.6%) of injection 0.2ml causes the degree of depth, large tracts of land, persistent pain stimulation in mouse peritoneal, makes mice produce writhing response, and record is respectively organized mice and produced the number of times of writhing response in 20 minutes, and takes statistics.
The pain that the L-theanine suppresses chemical stimulation the results are shown in Table 5.
Table 5 L-theanine to the analgesic activity (writhing method) of mice (X ± SD, n=10)
| Group | Number of animals (only) | Turn round body number of times (number of times/20min) |
| Dosage group high dose group in the matched group low dose group | 10 10 10 10 | 38.84±9.41 31.25±10.13 28.36±11.40 25.81±9.94 |
Table 5 shows that the L-theanine can effectively suppress the pain that chemical stimulation produces.
Three, the present invention is to the therapeutic effect of rheumatic arthritis, patient with rheumatoid arthritis
1, physical data
This group patient 14 examples, rheumatic arthritis 6 examples, male 2 examples, women 4 examples, age minimum 15, maximum 71 years old, the course of disease 2 to 26 years; Rheumatoid arthritis 8 examples, male 3 examples, women 5 examples, minimum 20 years old of age, maximum 51 years old, course of disease 1-13.All case is carried out ESR, CRP, RF, Hb, WBC, BPC, BUN, blood Cr, SGPT, routine urianlysis, and some cases carries out serum il-2R and CD8 Detection of antigen.
2, Therapeutic Method
Oral L-theanine (purity 99%), a 0.4-0.8 gram, 3 times on the one, 60 days courses of treatment.
3, criterion of therapeutical effect
(1) rheumatic arthritis criterion of therapeutical effect
Produce effects: symptom and sign are most of to take a turn for the better (the redness and swelling of joints burning pain disappears or has mild pain, functional activity to recover normal substantially), and lab testing is all in normal range;
Effectively: subjective symptoms and sign alleviate, and dysfunction is improved, and lab testing take a favorable turn;
Invalid: symptom, sign, lab testing all do not have improvement.
(2) rheumatoid arthritis criterion of therapeutical effect
Produce effects: symptom and sign are most of to take a turn for the better, and lab testing and X ray examination have remarkable improvement;
Effectively: symptom and sign partly improvement or lab testing and X ray examination are clearly better;
Invalid: symptom, sign, laboratory and X ray examination all do not have improvement.
4, therapeutic outcome
(1) treatment rheumatic arthritis curative effect
Table 6 treatment rheumatic arthritis curative effect
| The example number | Produce effects | Effectively | Invalid | Effectively total |
| Example number % | Example number % | Example number % | Example number % | |
| 6 | 4 66.7 | 2 33.3 | 6 100.0 |
(2) treatment rheumatoid arthritis curative effect
Table 7 treatment rheumatoid arthritis curative effect
| The example number | Produce effects | Effectively | Invalid | Effectively total |
| Example number % | Example number % | Example number % | Example number % | |
| 8 | 4 50.0 | 3 37.5 | 1 12.5 | 7 87.5 |
Industrial applicability
The preparation method of theanine has many reports, and the theanine commodity (raw material) of existing suitability for industrialized production, prepare arthritic medicine or the health product for the treatment of and/or preventing of the present invention with theanine, having the common medicine or the equipment of health product now can realize, can suitability for industrialized production.The present invention has enlarged the range of application of theanine, has improved its exploitation and has been worth.Treat and/or prevent arthritis with the theanine preparation, especially preparation treats and/or prevents the medicine or the health product of rheumatism or rheumatoid arthrosis, and technology is simple, good effect, and raw material is easy to get, and has industrial applicibility.
The specific embodiment
Embodiment 1
L-theanine (98%-100%) 500 grams, lactose 2500 grams.Component is stirred, encapsulated, every filling 0.3 gram.Make 10000 of L-theanine capsules, every capsules contains 50 milligrams of L-theanine.
Embodiment 2
L-theanine 1000 grams.The L-theanine is encapsulated, every filling 0.1 gram.Make 10000 of theanine capsules.
Embodiment 3
L-theanine 500 grams, starch 2500 grams.Component is stirred, encapsulated, every filling 0.3 gram.Make 10000 of L-theanine capsules, every capsules contains 50 milligrams of L-theanine.
Embodiment 4
L-theanine 1000 grams, sucrose 1000 grams, starch 1000 grams.Component is stirred, and moistening, tabletting makes 10000 in L-theanine tablet, and every contains 100 milligrams of L-theanine.
Embodiment 5
L-theanine 200 grams, 9800 milliliters of distilled water, stevioside is an amount of.The L-theanine is dissolved in stirring and evenly mixing in the distilled water, adds stevioside, stirring and evenly mixing, bottling, every bottled 10ml, sterilization makes 1000 bottles of L-theanine oral liquids, and every bottle contains 200 milligrams of L-theanine.
Embodiment 6
L-theanine 500 grams, sucrose 1000 grams, xylitol 1000 grams, starch 500 grams.Each component is stirred, and moistening, tabletting makes 10000 of L-theanine sheets, and every contains 50 milligrams of theanine.
Embodiment 7
D-theanine (98%-100%) 500 grams, lactose 2500 grams.Component is stirred, encapsulated, every filling 0.3 gram.Make 10000 of D-theanine capsules, every capsules contains 50 milligrams of D-theanine.
Embodiment 8
DL-theanine 1000 grams.The DL-theanine is encapsulated, every filling 0.1 gram.Make 10000 of DL-theanine capsules.
Embodiment 9
D-theanine 500 grams, starch 2500 grams.Component is stirred, encapsulated, every filling 0.3 gram.Make 10000 of D-theanine capsules, every capsules contains 50 milligrams of D-theanine.
Embodiment 10
DL-theanine 1000 grams, sucrose 1000 grams, starch 1000 grams.Component is stirred, and moistening, tabletting makes 10000 in DL-theanine tablet, and every contains 100 milligrams of DL-theanine.
Embodiment 11
L-theanine, each 100 gram of D-theanine, 9800 milliliters of distilled water, stevioside is an amount of.Theanine is dissolved in stirring and evenly mixing in the distilled water, adds stevioside, stirring and evenly mixing, bottling, every bottled 10ml, sterilization makes 1000 bottles of L-theanine and D-theanine oral liquids, and every bottle contains each 100 milligrams of L-theanine, D-theanine.
Embodiment 12
L-theanine, each 200 gram of DL-theanine, D-theanine 100 grams, sucrose 1000 grams, xylitol 1000 grams, starch 500 grams.Each component is stirred, and moistening, tabletting makes 10000 of three kinds of tea blend propylhomoserin sheets, and every contains 50 milligrams of theanine.
Claims (10)
1. theanine treats and/or prevents application in arthritic medicine or the health product in preparation.
2. theanine treats and/or prevents the medicine of rheumatic arthritis or the application in the health product in preparation.
3. theanine treats and/or prevents the medicine of rheumatoid arthritis or the application in the health product in preparation.
4. according to the arbitrary described application of claim 1 to 3, it is characterized in that described treating and/or preventing is treatment.
5. according to the arbitrary described application of claim 1 to 3, it is characterized in that described treating and/or preventing is prevention.
6. according to the arbitrary described application of claim 1 to 3, it is characterized in that described medicine or health product are medicine.
7. according to the arbitrary described application of claim 1 to 3, it is characterized in that described medicine or health product are health product.
8. according to the arbitrary described application of claim 1 to 3, it is characterized in that described treating and/or preventing to eliminating or inhibition arthritis pain.
9. according to the arbitrary described application of claim 1 to 3, it is characterized in that the mass percentage content of described theanine in medicine or health product is 1% to 100%.
10. according to the arbitrary described application of claim 1 to 3, it is characterized in that described theanine is the L-theanine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510200859 CN1985814A (en) | 2005-12-23 | 2005-12-23 | Monomer medicine for treating rheumatic arthritis and rheumatoid arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510200859 CN1985814A (en) | 2005-12-23 | 2005-12-23 | Monomer medicine for treating rheumatic arthritis and rheumatoid arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1985814A true CN1985814A (en) | 2007-06-27 |
Family
ID=38182841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510200859 Pending CN1985814A (en) | 2005-12-23 | 2005-12-23 | Monomer medicine for treating rheumatic arthritis and rheumatoid arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1985814A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107343886A (en) * | 2017-05-05 | 2017-11-14 | 广东省农业科学院茶叶研究所 | Tea component is suppressing the application of aspect of inflammation |
| US9918986B2 (en) | 2013-07-04 | 2018-03-20 | University College Cardiff Consultants Limited | Methods and compounds for preventing osteoarthritis |
| CN109043245A (en) * | 2018-05-17 | 2018-12-21 | 安徽农业大学 | The drinks and preparation method thereof for easing pain and diminishing inflammation containing L-thiamine |
-
2005
- 2005-12-23 CN CN 200510200859 patent/CN1985814A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9918986B2 (en) | 2013-07-04 | 2018-03-20 | University College Cardiff Consultants Limited | Methods and compounds for preventing osteoarthritis |
| CN107343886A (en) * | 2017-05-05 | 2017-11-14 | 广东省农业科学院茶叶研究所 | Tea component is suppressing the application of aspect of inflammation |
| CN109043245A (en) * | 2018-05-17 | 2018-12-21 | 安徽农业大学 | The drinks and preparation method thereof for easing pain and diminishing inflammation containing L-thiamine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103182049B (en) | Preparation method of pharmaceutical composition preparation treating apoplexy sequelae | |
| ES2315271T3 (en) | MEDICATION THAT CONTAINS ANEMONINE AS AN EFFECTIVE COMPONENT TO TREAT ASEPTIC INFLAMMATION. | |
| US20080286388A1 (en) | Pharmaceutical Composition and Non Dependence Coffee Comprising Edible Carboxylic Acid and/or Its Acid Salts and Coffeine | |
| CN105504076A (en) | Tetrastigma hemsleyanum Diels et Gilg root tuber polysaccharide with anti-pyretic and anti-inflammatory functions and application of Tetrastigma hemsleyanum Diels et Gilg root tuber polysaccharide | |
| CN110916033A (en) | A kind of uric acid-lowering beverage and preparation method thereof | |
| CN100998650A (en) | Use of cinnamonum cassia for treating diabetes, its products and preparing method | |
| CN101744844B (en) | Fulvic acid or sodium fulvic acid substance with hypoglycemic effect | |
| CN108245531B (en) | Composition for improving gastrointestinal tract function and preventing and treating constipation | |
| CN1985814A (en) | Monomer medicine for treating rheumatic arthritis and rheumatoid arthritis | |
| JP7157253B2 (en) | Chinese herbal composition for enema constipation, its preparation method and its use | |
| CN108434189A (en) | A kind of floral disc of sunflower general flavone and its extraction process and application | |
| CN1977835A (en) | Monomer medicine for treating ankylosing spondylitis | |
| CN108743809B (en) | Throat clearing composition and preparation method and application thereof | |
| CN101120977B (en) | Medicine for treating tumor | |
| CN103405724B (en) | A kind of Chinese medicine composition and preparation method thereof | |
| CN113476562A (en) | Composition and preparation method and application thereof | |
| KR101331913B1 (en) | Bambusae Caulis extracts showing a good therapeutic effect on osteoarthritis and its pharmaceutical compositions containing the same | |
| CN104825702A (en) | Composition capable of reducing fat and supplying nutrients and preparation method thereof | |
| CN117982597B (en) | Traditional Chinese medicine compositions for improving sleep, their preparation methods and applications | |
| CN110101679A (en) | Micro- effervescent tablet of seaweed sodium bicarbonate and its preparation method and application | |
| CN101849931A (en) | Medicament for treating encephalatrophy or encephalatrophic dementia | |
| CN115025173A (en) | Application of cannabidiol CBD (CBD) -containing extract in sleep assisting medicine | |
| CN108477607A (en) | A kind of nutraceutical improving children and infantal sleeping | |
| CN103705775B (en) | One protects the liver analgesia Chinese medicine composition and preparation method thereof | |
| CN106727627A (en) | A kind of medicine for the treatment of cancer and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |